Long-term results of OKT3-treated renal transplant recipients.
Tanabe
K
K
Department of Urology and Surgery, Kidney Center, Tokyo Women's Medical College, Japan.
Takahashi
K
K
Sonda
K
K
Tokumoto
T
T
Koga
S
S
Nakazawa
H
H
Goya
N
N
Yagisawa
T
T
Fuchinoue
S
S
Kawai
T
T
Toma
H
H
Ota
K
K
D000328:Adult; D003404:Creatinine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D003404:Creatinine